Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Levi Garraway

Levi Garraway

Chief Medical Officer, Genentech

Appears in 2 stories

Notable Quotes

"Today's approval represents an important step forward for people newly diagnosed with chronic lymphocytic leukemia." — Levi Garraway, upon FDA approval

Fenebrutinib has shown unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive MS.

Stories

Targeted drug combinations replace chemotherapy for common leukemia

New Capabilities

Oversaw Genentech's role in the venetoclax approval

On February 20, 2026, the FDA approved venetoclax and acalabrutinib for chronic lymphocytic leukemia (CLL), the most common adult leukemia in Western countries, with roughly 23,000 new American cases each year. In a trial of 867 patients, 77% remained cancer-free at three years.

Updated May 29

The BTK inhibitor race for multiple sclerosis

New Capabilities

Overseeing fenebrutinib's path to approval

The FDA rejected Sanofi's tolebrutinib for progressive MS on December 28, 2025—a crushing blow for a drug that had won Breakthrough Therapy status and became the first BTK inhibitor approved anywhere in the world. Meanwhile, Roche's rival drug fenebrutinib is racing toward approval after strong Phase 3 results, and Merck's evobrutinib crashed out entirely. Three pharma giants bet billions that brain-penetrating BTK inhibitors could finally slow the relentless neurodegeneration that leaves MS patients in wheelchairs, and only one looks likely to reach the finish line first.

Updated May 16